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Development of drug resistance is the inevitable consequence of incomplete suppression of virus plasma levels in
HIV-1-infected patients treated with highly active antiretroviral therapy. Resistance mutations previously characterized have
been found in B subtype viruses of developed countries. Moreover, mutation profiles for non-B and more divergent B subtype
viruses found in developing countries shall be analyzed together with their ex vivo phenotyping in order to establish an exact
correlation between the genotyping data and the clinical management counseling for those uncommon virus subtypes. In the
present study, we evaluated the mutation profile for individuals infected with B subtype and non-B subtype viruses. Viral DNA
fragments corresponding to the RT gene were amplified, sequenced, and subtyped. Phenotyping analysis for reverse
transcriptase nucleoside (NRTI) and nonnucleoside inhibitor susceptibility was performed using the recombinant virus assay
technology. Brazilian non-B subtypes (subtype F, n 5 4, and subtype A, n 5 1) isolates showed essentially the same B subtype
mutation profile, presenting an NRTI drug resistance with similar MIC50% and MIC90% values for all drugs analyzed
regardless of their subtypes. A strong cross-resistance phenotype among AZT, 3TC, and abacavir could be seen in all isolates
analyzed. A novel result was that some RT sequences not only revealed the presence of G333D/E mutations but also
correlated to the presence of mutation T386I that could abrogate the M184V-surpassing effect of L210W or L210W plus
G333D/E. These findings suggest that Brazilian non-B subtype HIV-1 strains use an identical RT drug resistance mutation
pattern when compared to B isolates and will contribute to the validation of the genotypic and phenotypic tests in these
predominant worldwide-spread viral variants. © 2000 Academic Press
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Recent development of a new generation of drugs
against HIV led to drastic changes in antiretroviral ther-
apy and treatment of AIDS. Antiretroviral drug combina-
tions including two nucleoside reverse transcriptase in-
hibitors (NRTI) and/or nonnucleoside reverse transcrip-
tase inhibitors (NNRTI) and one or more protease
inhibitors can reduce the viral load in plasma to unde-
tectable levels and provide durable clinical benefits (Col-
lier et al., 1996; Vella et al., 1996). However, complete
uppression of HIV-1 replication is rarely achieved with
ono- and bitherapies, which have a transient effect due
o virus drug resistance (Carpenter et al., 1996). For that
eason, current guidelines to obtain benefits from antivi-
al therapy recommend at least a triple-drug combina-
ion, the so-called highly active antiretroviral therapy
HAART). Not all patients respond to HAART and the
1 To whom reprint requests should be addressed at Universidade
ederal do Rio de Janeiro, CCS, IB/Dep. Gene´tica, Bloco A, sala 121, 2°r
d
ndar, Cidade Universita´ria, Rio de Janeiro, RJ, 21944-970, Brazil. Fax:
551211280-0994. E-mail: atanuri@biologia.ufrj.br.
107evelopment of drug resistance remains one of the most
erious obstacles to sustained suppression of HIV (Sha-
er et al., 1998; Ledergerber et al., 1999). Continuous in
ivo HIV replication and the error-prone nature of the
iral reverse transcriptase are the driving forces for gen-
ration of drug resistance (Coffin, 1996). Moreover, re-
ent studies identified a replication-competent HIV-1 res-
rvoir in patients under HAART, raising serious concern
egarding whether antiviral therapy can eradicate HIV-1
Finzi et al., 1997; Zhang et al., 1999; Furtado et al., 1999).
HIV replicates as complex and dynamic distributions
f mutant genomes termed viral quasispecies (Domingo
t al., 1997), which constitute an enormous reservoir of
enetic variants. This quasispecies structure represents
n important obstacle in the control of the infection
hrough drug therapy (Domingo et al., 1997). The re-
eated selection of HIV-1 variants resistant to antiretro-
iral agents is an important concern in the treatment of
atients under HAART with any of the major nucleoside
nd nonnucleoside reverse transcriptase inhibitors (for
etails see Fig. 4 and the web site http://www.viral-esistance.com). However, almost all studies on HIV-1
rug susceptibility have been performed in developed
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108 CARIDE ET AL.countries, where subtype B still dominates the epidemic.
Similarly, the resistance mutations selected during anti-
retroviral treatment were only studied with subtype-B-
infected patients. These facts make the study of non-B
subtype isolates resistant to antiretroviral agents an im-
portant issue for the characterization of non-B mutations
related to drug resistance.
As the largest country in South America, Brazil has
also been the one most heavily affected by the HIV/AIDS
epidemic. The Brazilian epidemic is characterized by
multiple HIV-1 group M subtypes, primarily subtype B
and the less prevalent subtype F, but also subtypes C
and D (Morgado et al., 1994; Sabino et al., 1996; Tanuri et
al., 1999). Subtype F is the most prevalent non-B variant
and represents approximately 18% of HIV-1 isolates from
southeastern Brazilian cities. An increasing prevalence
of subtype C infections has also been recognized in
Brazilian southernmost states (WHO Network for HIV
Isolation and Characterization, 1994). In addition, the
presence of recombinants, potential mosaics, and dual
infections has been documented (Janini et al., 1996; Corl-
nelissen et al., 1997). Those group M subtypes found in
Brazil are also originally endemic to various developing
countries throughout the world (McCutchan et al., 1996;
Janssens et al., 1997), and they need to be evaluated for
their susceptibility to RT inhibitors and mutation profiles
related to drug resistance. This study documents the
genotypic and phenotypic analyses of reverse transcrip-
T
Epidemiological and Clinic
Patient Gendera
Risk
factorb
First
serology
(years)
RRJ15 M IDU 13
RRJ16 M Ho 2
RRJ17 M Het 3
RRJ18 M VT 9
ERRJ19 F Het 9
ERRJ20 M Ho 3
ERRJ21 F Het 1
ERRJ22 M Ho 3
ERRJ23 M Ho 6
ERRJ24 M Ho 4
ERRJ25 M NAe 3
RRJ26 M Ho 6
RRJ27 F IDU 4
RRJ28 M Ho 2
a M, male; F, female.
b Het, heterosexual contact; Ho, homosexual contact; IDU, intraveno
c ARV regimen in the time of sample collection. Drugs indicated are
(saquinavir), INV (indinavir), and RTV (ritonavir).
d The last viral load (log) and CD4 counts (cells/mm3) evaluated jus
e NA, information not available.tase gene from 14 HIV-1 B and non-B subtype isolates
infecting Brazilian patients who failed HAART.RESULTS
All patients studied were in stage 4 based on the WHO
staging system and they were all antiretroviral experi-
enced, with exposure to two to five different nucleoside
analogues for a mean treatment duration of 32 months
(31.93 6 3.79 mean SD). NNRTI were absent from the
drug regimens of study patients, and ritonavir, saquina-
vir, and indinavir were the protease inhibitors utilized to
compose the HAART cocktail (Table 1). Most patients
were under different NRTI mono- and bitherapies previ-
ous to HAART adherence (Table 1 and Fig. 1).
To determine the RT gene subtype classification of
these 14 HAART nonresponder isolates, phylogenetic
trees were performed based on “palm and finger” RT
region sequences (Fig. 2). Five of 14 (35.6%) non-B sub-
type individuals were found in this group of samples.
Four specimens were subtype F, and other 9 samples
(64.4%) belong to subtype B. Sample ERRJ16 couldn’t be
assigned to any specific subtype group based on the RT
region analyzed, presenting a bootstrap value of 36%
with the nearest F subtype branch. Of note, most of the
samples presented branch lengths much larger than the
A, B, and F standard sequences used to construct the
phylogenetic tree. In order to clarify the subtype assign-
ment of sample ERRJ16, the gag-p24 region of this isolate
and all non-B infected individuals were analyzed. Figure
3 shows the phylogenetic tree representing the analysis
mation for Study Isolates
me under
HAART
months) ARV therapyc
Virus load (VL) and
CD4 countsd
VL CD4
18 D4T/3TC/SQV/RTV 6.49 26
15 D4T/3TC/INV 6.23 09
14 D4T/3TC/INV 5.43 110
8 AZT/3TC/INV 4.57 205
10 AZT/3TC/INV 4.53 411
16 D4T/ddI/SQV/RTV 6.13 26
14 AZT/ddI/INV 5.66 506
22 D4T/SQV/RTV 5.49 249
17 D4T/3TC/RTV 5.81 250
26 AZT/ddI/SQV/RTV 5.33 189
31 AZT/3TC/SQV/RTV 4.98 5
28 3TC/RTV/SQV 5.20 243
11 AZT/3TC/RTV 5.54 190
15 D4T/3TC/RTV 5.36 93
g use; VT, vertical transmission.
zidovudine), 3TC (lamivudine), ddI (didanosine), D4T (stavudine), SQV
the sample collection.ABLE 1
al Infor
Ti
(
us dru
AZT (of these samples where longer branch lengths continued
to be observed when compared to the standards se-
tients in
109NON-B HIV-1 SUBTYPE RT GENOTYPING AND PHENOTYPINGquences. These results indicated that sample ERRJ16 is
of A subtype, while samples ERRJ15, ERRJ17, ERRJ18, and
ERRJ19 were grouped with subtype F clade.
Although all patients described here experienced
HAART failure, who were all experienced in previous
NRTI therapies, this cohort sampling population showed
a different treatment profile when individuals infected
with B subtype and non-B subtype viruses were com-
pared (Fig. 1). The Brazilian non-B viruses induced a
therapy failure in patients with comparable times of treat-
ment (27.8 6 4.6 months average 6 mean SD, versus
FIG. 1. Graphical representation of time under treatment with NRTIs
treatments stopped, to be followed up for this study, in April 1998. Dash
of at least one PI to the regimen. The double line segregates the nine pa
(bottom).34.2 6 5.3 months of B-virus-infected patients; one-tailed
unpaired t test, P 5 0.1918) to the B counterpart as wellthe number of NRTI drugs used during this time of treat-
ment (3.6 6 0.2 drug mean 6 mean SD versus 4.1 6 0.3
drug mean of B-virus-infected patients; one-tailed un-
paired t test, P 5 0.1279).
In order to study the genotypes for NRTI and NNRTI
resistance, all 14 amino acid sequences of reverse tran-
scriptase palm and finger regions were deduced and
aligned. The alignment of 14 B and non-B Brazilian sam-
ples is depicted in Fig. 4. Overall, the mutation patterns
found were compatible with the drug regimen imple-
mented in each patient. The main mutation pattern found
ch patient infected with B subtype virus and non-B subtype virus. All
ical lines represent the start of adherence to HAART, with the addition
fected with B-subtype isolates (top) from those five with non-B isolatesfor ea
ed vertin Brazilian isolates regardless of the subtype involved
was the association of K70R, M184V, and T215F/Y. Mu-
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110 CARIDE ET AL.tation L210W was found in samples ERRJ16, ERRJ18,
ERRJ23, ERRJ25, ERRJ26, ERRJ27, and ERRJ28. The mul-
tidrug resistance mutation Q151M was found in sample
ERRJ20 and in this case was associated with Y115F and
F116Y. Mutations related to NNRTI resistance were ab-
sent in all 14 samples studied.
Phenotyping analysis was performed using the recom-
binant virus assay technology (VIRCO). Recombinant vi-
rus was generated carrying the 2.2-kb pol fragment am-
plified from each of the 14 samples and exposed to NRTI
(AZT, 3TC, ddI, ddC, and d4T) and NNRTI (nevirapine,
delavirdine, efavirenz) in MT4 cell cultured. The RT phe-
notyping results are shown in Table 2. Most of the sam-
ples (9 of 14) were simultaneously resistant to AZT and
3TC. This was mainly related to the presence of L210W
and/or G333D/E associated with K70R, M184V, and
T215F/Y mutations. One exception for this was found in
sample ERRJ20 where the multidrug resistance mutation
pattern (Q151M, Y115F, and F116Y) was identified. In fact,
L210W mutation alone, or in association with G333D/E,
FIG. 2. Phylogenetic analysis of HIV RT isolates compared to 18
reference HIV-1 group M subtypes and 2 reference HIV-1 group O,
available in the Los Alamos database. Sequence cpz was used as the
outgroup. Aligned fragments were analyzed as described under Mate-
rials and Methods, and bootstrap values for 2000 replicates are listed
at the major subtype branches. Brazilian isolates sequenced in this
study are italicized. The scale bar shows the ratio of nucleotide sub-
stitution for a given horizontal branch length. Vertical distances are for
clarity only.was responsible for abolishing the AZT-resistance sup-
pressive background due to the M184V mutation. Themutational feature of the uppermost C-terminal region of
RT was established by analysis of the mutation profile
reports of the 2.2-kb pol amplicons generated previous to
he phenotyping assay. This analysis not only revealed
he presence of G333D/E mutations in some RT se-
uences but also correlated with the presence of a novel
utation T386I that could abrogate the M184V-surpass-
ng effect of L210W or L210W plus G333D/E (Table 3). At
ifferent levels, the M184V background interference over
he AZT-resistance mutation profile is biased by the pres-
nce of L210W or L210W 1 G333D/E and favored by the
386I mutation. The aspartic acid residue at position 333
ssociated to L210W seems to be more effective in doing
o than its glutamic acid counterpart, as revealed by
ifferent IC50% AZT fold resistance between samples
RRJ25 and -27.
Most of these AZT and 3TC resistant strains were
ross-resistant to abacavir, an antiretroviral compound
ot used in these patients. Although most of patients
ere using ddI in their drug regimen, only three samples
ERRJ16, ERRJ20, and ERRJ27) showed a low-level resis-
ance to this NRTI. ddI resistance in sample ERRJ27 was
pparently associated to the L74I mutation. On the other
and, the ddI resistance in samples ERRJ20 was related
o Q151M multidrug resistance mutation. No main muta-
ions related to ddI resistance were found in sample
FIG. 3. Phylogenetic analysis of HIV p24 gag isolates. Sequence
isolates were compared to 16 reference HIV-1 group M subtypes and 2
reference HIV-1 group O, available in the Los Alamos database. Se-
quence cpz was used as the outgroup. Aligned fragments were ana-
lyzed as described under Materials and Methods, and bootstrap values
for 2000 replicates are listed at the major subtype branches. Brazilian
isolates sequenced in this study are italicized. The scale bar shows the
ratio of nucleotide substitution for a given horizontal branch length.
Vertical distances are for clarity only.
erlined
111NON-B HIV-1 SUBTYPE RT GENOTYPING AND PHENOTYPINGERRJ16. In the same way, although D4T was heavily
used, only sample ERRJ20 showed some level of resis-
tance to this analog probably related to the Q151M mul-
FIG. 4. Amino acid alignment of RT “palm and finger” sequences. Mu
top (AZT, zidovudine; 3TC, lamividine; ddI, didanosine; ddC, zalcitab
efavirenz; MNR, multinucleoside resistance (see web site: http://www.v
RT isolates is shown at the bottom. Nucleotide sequences were transl
of B subtype, deduced from the Los Alamos database. Boldface letter
NNRTI, italicized letters refer to secondary substitutions, and the und
denote sequence identity with the consensus sequence.tidrug resistance mutation. Of note, no level of resistance
to nevirapine, delavirdine, or efavirenz could be ob-served in all samples studied. Although the mutation
V106I could be found in sample ERRJ25, no level of
resistance to nevirapine was observed by the phenotyp-
commonly related to NRTI and NNRTI resistance are depicted at the
T, stavudine; ABC, abacavir; NVP, nevirapine; DLV, delavirdine; EFV,
istance.com), and alignment of deduced protein sequence from HIV-1
ligned, and compared with the SF2 isolate sequence as a consensus
ate the substitutions that confer primary drug resistance to NRTI and
letters indicate the amino acid differences between subtypes. Dotstations
ine; D4
iral-res
ated, a
s indicing assay. By taking all these results together we could
not observe any significant difference in the level of
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112 CARIDE ET AL.phenotypic resistance to NRTI when B and non-B sub-
type isolates were compared.
DISCUSSION
Plasma viral load (VL) is commonly used as an inde-
pendent predictor of clinical progression (Mellors et al.,
1995) and is a useful tool for monitoring response to
therapy (Ledergerber et al., 1999). The initial choice of
he 14 HAART nonresponder patients was based on the
T
Susceptibility to Reverse Transcription Inhibitors Obtained with R
Phenotype (fold Resistance)a
Patient RT subtypec AZTd 3TCd ddId DDCd D4Td ABC
ERRJ15 F 3.1 .93.4 1.6 1.2 0.6 1
ERRJ16 Ae .79.1 .130.6 6.2 2.7 3.1 8.7
ERRJ17 F 8.8 .130.6 1.6 1.7 2.6 4
ERRJ18 F 1.7 .93.4 3 1.7 0.8 2.2
ERRJ19 F 1.9 .93.4 2.8 1.4 0.7 4.5
RRJ20 B .65.1 .74.7 11.2 8.4 1.9 10.5
RRJ21 B 15.3 4.8 1.6 0.7 1.3 4.8
RRJ22 B 2.1 .130.6 3.8 2.3 0.6 5.9
RRJ23 B 7.2 .130.6 2.3 2.6 3.7 8.8
RRJ24 B .79.1 9.3 1.6 1.1 2.5 10.3
RRJ25 B 38.8 11.7 1.3 1.3 3.4 2
RRJ26 B 66.4 5.7 1.7 1.6 2.6 3.5
RRJ27 B 7 .130.6 4.3 3.7 1.6 8.3
RRJ28 B 31.5 .130.6 2.1 3.2 2.5 9.1
a Fold increase in the mean IC50 relative to the mean IC50 of the wild
ignificant.
b The boldface letter indicates the substitution that confers primary
c Subtype obtained in the phylogenetic trees constructed with the p
d AZT, zidovudine; 3TC, lamividine; ddI, didanosine; ddC, zalcitabine; D
EFV, efavirenz.
e Subtype based on gag-p24 phylogeny.
TABLE 3
Susceptibility to AZT in Samples Carrying L210W, G333D,
and/or T386I in the M184V Background
L210W G333D T386I AZT fold resistancea,b
ERRJ17 1c 2 2 .79.1
ERRJ29 1 2 2 38.8
ERRJ26 1 1 1 31.5
ERRJ24 1 2 1 7.2
ERRJ28 1 1 (G333E) 1 7
ERRJ23 2 2 1 (T386V) 2.1
ERRJ20 2 1 2 1.9
ERRJ19 1 2 1 1.7
a Fold increase in the mean IC50% relative to the mean IC50% of the
ild type.
b Boldface indicate resistance level $fourfold as determined to be
significant.c
(
c 1 and 2 represent the presence and absence of mutation, respec-
tively.L response, which was at least 2 logs higher than that
f HAART responders in the AIDS clinics of the two
ospitals enrolled in this study (data not shown). By
sing this virological criterion, we could find mutations
elated to NRTI resistance in all patients analyzed and
hese substitutions accorded with the drug regimen im-
lemented. Overall, the reverse transcriptase genotyping
orroborated the phenotypic resistance assay results for
ach isolate, regardless of the virus subtype. We could
bserve a correlation between L210W and AZT/3TC dual
esistance, except when coexisting with T386I. Previous
tudies have shown that just one primary substitution
as sufficient for in vivo development of zidovudine re-
istance at significant levels, but multiple substitutions
hat include G333D/E and/or L210W are required for the
ame level of zidovudine resistance in strains harboring
he M184V mutation related to 3TC resistance. This need
or multiple substitutions may be one of the mechanisms
hat explains the sustained antiretroviral response of the
TC–zidovudine combination (Nijhuis et al., 1997). In Bra-
ilian samples, mutational analysis indicates that L210W
s far more prevalent and it was found in 67% of the
solates (four of six) that showed this mutation together
ith the M184V mutation. The substitution G333D/E is
ikely to have a minor role in the resistance phenotype,
enerally related to L210W. When it was found apart from
210W, even in the absence of T386I, G333D could not
inant Viruses with HAART Nonresponders Patients pol Sequence
Genotypeb
d NVPd DLVd EFVd RT resistance mutation
0.7 0.5 ,0.5 D67N, T69D, K70R, M184V, T215F, K219Q
0.5 0.8 0.8 M41L, D67N, M184V, L210W, T215Y, K219N
1.6 1.6 0.6 D67N, T69N, K70R, M184V, T215F, K219Q
1.1 2.6 0.6 K70R, M184V, L210W, T215Y, K219Q
2 1.1 1 D67N, K70R, M184V, T215Y, K219E
,0.3 0.5 0.6 V75I, F77L, Y115F, F116Y, Q151M, M184V
0.9 0.9 1 M41L, D67N, K70R, T215Y
0.9 0.6 0.8 M41L, M184V, T215Y
1.6 0.6 0.8 M41L, D67N, M184V, L210W, T215Y
2 3.4 1.5 D67N, T69D, K70R, T215F, K219Q
1.4 0.3 ,0.6 M41L, D67N, V106I, L210W, T215Y
2.3 1.6 0.8 M41L, L210W, T215Y
1.4 0.5 1 M41L, L74I, M184V, L210W, T215Y
1 0.2 0.9 M41L, D67N, T69D, M184V, L210W, T215Y
oldface letters indicate resistance level $fourfold as determined to be
sistance to PI.
sequence.
vudine; ABC, abacavir; ADV, adefovir; NVP, nevirapine; DLV, delavirdine;ABLE 2
ecomb
d ADV
0.3
1.8
1
1.3
1.9
0.2
1.2
0.7
2.7
5.4
2
1.9
1.4
2.2
type. B
drug re
rotease
4T, staorrelate with the dual AZT/3TC resistance phenotype
sample ERRJ20). Although this is a potentially interest-
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113NON-B HIV-1 SUBTYPE RT GENOTYPING AND PHENOTYPINGing finding, it needs to be confirmed by cloning this
substitution alone and with the other mutations in a
different RT background before its significance can be
assessed. The mutation Q151M found in sample ERRJ20,
together with a secondary mutation pattern (A62V, V75I,
F77L, and F116Y) correlated with a multinucleoside re-
sistance phenotype, was responsible for another case of
AZT/3TC resistance in the presence of M184V.
There was a strong association between the resis-
tance to AZT and 3TC and the loss of sensitivity to
abacavir, an antiretroviral compound never used in the
patients’ regimen. This observation was previously re-
ported in a European study where cross-resistance was
not commonly observed in that lamivudine-treated cohort
and M184V mutation per se was not expected to com-
promise subsequent treatment with NRTIs such as di-
danosine–stavudine or combinations containing aba-
cavir (Miller et al., 1998). Although all samples showed
esistance to NRTIs at genotypic and phenotypic levels,
here were no mutations related to NNRTI resistance as
ell as phenotypic resistance to this class of antiretro-
iral drugs. This work shows that these two distinct
ubtypes (B and F) use basically the same mutation
rofile to reach resistant phenotypes.
The observation of large branch lengths in the phylo-
enetic trees for Brazilian resistant sequences is prob-
bly an effect of the accumulation of primary and sec-
ndary mutations related to reverse transcriptase inhib-
tor resistance due to drug-selective pressure.
Studies with isolates from untreated subjects showed
hat mutations related to protease inhibitors, NRTI, and
NRTI resistance could be found in B and non-B subtype
iruses as natural polymorphisms suggesting that the
IV-1 pol region has sufficient in vivo fitness flexibility for
varying in critical sites (Lech et al., 1996; Cornelissen et
al., 1996). It is important to mention that although subtype
B and F RT sequences differ from about 30 nucleotides
and only two amino acids in the palm–finger region,
these mutations and substitutions are not related to NRTI
or NNRTI resistance (Brindeiro et al., 1999). In the same
way, in vitro studies performed with subtypes A, B, C, and
E (Palmer et al., 1998) as well as group O (Descamps et
al., 1997b) demonstrated similar drug susceptibility
among these variants and subtype B. On the other hand,
subtype D isolates showed a higher MIC50% and
MIC90% when compared with the other subtypes studied
and this was correlated with the faster in vitro growth
pattern (Palmer et al., 1998). In the same way, subtype G
strain showed a decreased susceptibility to protease
inhibitors and presented an M36I substitution as a nat-
ural polymorphism (Descamps et al., 1997a). Additionally,
B and non-B isolates have comparable levels of resis-
tance in the in vitro tests performed, suggesting that
these mutations induce similar modifications in the en-
zyme three-dimensional structure.
Non-B subtype infections are becoming more commonin Europe and North America (Brodine et al., 1995;
Fransen et al., 1996; Lasky et al., 1997) and these variants
dominate the epidemic in the rest of the world (Mc-
Cutchan et al., 1996). Moreover, some countries in the
developing world are sponsoring large HIV treatment
programs with drug combinations including NRTI and
NNRTI. The data presented in this work clearly show
similar mutation patterns related to NRTI resistance and
the phenotypic level of drug resistance in vitro between
Brazilian B and non-B isolates. These observations may
contribute to the validation of the genotypic and pheno-
typic tests in these predominant worldwide-spread viral
variants.
MATERIALS AND METHODS
Samples. From April through December 1998, blood
samples were collected at Hospital Universita´rio Gaffre´e
& Guinle and Hospital dos Servidores do Estado in Rio
de Janeiro. Fourteen samples were selected prospec-
tively and the inclusion criteria for the study were that
patients have AIDS (CD4 counts ,200/mm3) and have
had at least 6 months in HAART. The basic criteria to
segregate these samples were the viral loads after
HAART implementation. A viral load drop lower than 1
log after implementation of HAART was considered a
failure in the antiretroviral therapy. These selected pa-
tients were also evaluated for compliance to the treat-
ment and only individuals referring good compliance to
antiretroviral therapy were included in this study. All
patients were asked to read and sign a consent form
before sample collection. Epidemiological and clinical
parameters are summarized in Table 1 and Fig. I. Viral
load measurements were done with NASBA methodol-
ogy (Organon Teknika, The Netherlands). This method
has a lower limit of detection, around 400 copies of HIV
RNA/ml, and is able to measure with equal efficiency B
and non-B isolates in plasma (de Baar et al., 1999).
Nucleic acid extraction, cDNA synthesis, and polymer-
ase chain reaction (PCR). Genomic DNAs from PBMCs
and plasma viral RNA were isolated using a QIAamp
blood kit (Qiagen Inc., Chatsworth, CA) according to the
manufacturer’s protocol and stored at 270°C. The syn-
thesis of cDNA occurred in the presence of avian myelo-
blastosis virus RT (Stratagene) at 42°C. Two different
HIV-1 genomic regions were targeted for PCR amplifica-
tion: gag p24 (from provirus) and pol Rt (from provirus
and cDNA), using primers described in Table 4. Nested
PCR amplification was performed as previously de-
scribed (Tanuri et al., 1999; Janini et al., 1996) using for
oth HIV regions a mixture containing 5 ml of cDNA or
genomic DNA (or 2 ml of the outer PCR product), 5 ml of
103 Taq buffer, 5 ml of 25 mM MgCl2 solution, 1 ml of 10
M (each) deoxynucleoside triphosphates, 1 ml (25
pmol) of each PCR primer, 31.5 ml of H2O (or 34.5 ml for
the nested reaction), and 0.5 ml (2.5 U) of AmpliTaq
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114 CARIDE ET AL.polymerase (Perkin–Elmer). For both outer and nested
PCR rounds, 35 cycles were performed, with an anneal-
ing temperature of 57°C, extension at 72°C, and dena-
turation at 94°C over 30 s each. PCR products were
purified using QIAamp PCR purification kit (Qiagen Inc.)
according to the manufacturer’s instructions.
DNA sequencing. Both strands of the PCR fragments
ere directly sequenced using internal (nested) PCR
rimers and the ABI Prism dye terminator cycle sequenc-
ng reaction kit (Perkin–Elmer, Foster City, CA). The se-
uence reaction was fractionated and analyzed using an
utomated sequencer (ABI Model 310, Perkin–Elmer) ac-
ording to the manufacturer’s protocol. Sequences de-
cribed in this studied have been assigned the followed
enBank Accession Number: gag p24 (AF165562-66)
nd pol RT (AF180667-80).
Phylogenetic analyses. cDNA RT and provirus p24
equences were analyzed with the sequence editor
NASIS version 2.1 software (Hitachi, NJ) and manually
dited. Alignments were performed using CLUSTAL W
Thompson et al., 1994). For phylogenetic analyses, the
eighbor-joining method was used (Saitou and Nei,
987). Evolutionary distances were estimated using the
imura two-parameter method. Construction of trees and
heir bootstrap test were conducted using the computer
rogram MEGA (Kumar et al., 1993) with 2000 replica-
tions, with representative standards belonging to differ-
ent subtypes obtained from the database of Los Alamos
National Laboratory. The SIVcpz sequence was used as
an outgroup.
Phenotyping. The detection of HIV-1 phenotypic RT
inhibitor resistance was performed using a recombinant
virus assay technology (VIRCO). Briefly, HIV-1 RNA was
extracted from plasma samples, and a 2.2-kb fragment
containing the entire HIV-1 pol (protease and reverse
transcriptase) coding sequence was amplified by nested
reverse transcription PCR. Sequences were generated
using an ABI Prism automated sequencing machine and
analyzed in a HIV-genotyping software from VIRCO, con-
T
PCR Prim
HIV-1 genome
region
Primer
utility Primer name
Annealing regi
HIV-1 MN gen
Gagp24 Outer PCR M/O p24-1F 1180–1199
M/O p24-7R 1832–1850
Nested PCR M/O p24-2F 1243–1262
M/O p24-6R 1709–1727
Pol RT Outer PCR RT-9F 2485–2513
RT-12R 3249–3275
Nested PCR RT-1F 2619–2647
RT-4R 3246–3265firming the previous genotyping data. A mutation profile
report was generated for each sample when comparedwith the prototypic MN isolate RT sequence. The pool of
pol coding sequences of each sample was then cotrans-
fected into CD41 T lymphocytes (MT4) with the pGEMT3
(PRT plasmid carrying the defective pol HIV genomic
cDNA). Homologous recombination led to generation of
a chimeric virus containing pol sequences derived from
the patients’ virus. The susceptibility of the chimeric virus
to all currently available RT inhibitors was determined by
an MT4 cell-3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetra-
zolium bromide-based cell viability assay in an auto-
mated system as previously described (Hertogs et al.,
1998).
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